glp-1 insulin secretion JCI GLP-1 promotes insulin secretion. |
Description
Neuropsychopharmacology 44, 20542064
The performance of companies within the fund benefits from the clinical and commercial success of obesity drugs, which is an uncorrelated source of return in the market
Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, et al
79 Liraglutide 3.0 mg (Saxenda , produced by Novo Nordisk) is sanctioned for use in managing overweight and obesity in both the United States and Europe when combined with a reduced-calorie diet and physical exercise
People with type 2 diabetes have a two to three times higher baseline risk of pancreatitis compared to the general population due to shared metabolic risk factors
As prescribing rates climb, awareness of GLP-1 dermatologic effects becomes essential for safe and informed practice
